All CDK4 reagents are produced in house and quality controlled, including 2 CDK4 Antibody, 45 CDK4 Gene, 2 CDK4 IPKit, 1 CDK4 Lysate, 1 CDK4 Protein, 3 CDK4 qPCR. All CDK4 reagents are ready to use.
Recombinant CDK4 proteins are expressed by Baculovirus-Insect Cells with fusion tags as N-GST.
CDK4antibodies are validated with different applications, which are WB, IHC-P, ICC/IF, IF, IP, ELISA.
CDK4cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CDK4 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
CDK4 is a member of the Ser/Thr protein kinase family. It is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of CDK4 is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). CDK4 was shown to be responsible for the phosphorylation of retinoblastoma gene product. CDK4 is the ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. CDK4 has been shown to be mutated in some types of cancer, whilst a chromosomal rearrangement can lead to Cdk6 overexpression in lymphoma, leukemia and melanoma.